founder

创始人
  • 文章类型: Journal Article
    吴孟超自20世纪50年代以来一直从事肝胆外科的基础和临床研究,被公认为中国肝胆外科的创始人和先驱。在他60多年的职业生涯中,吴进行了16000多次手术,在肝胆外科取得了许多突破,肝癌信号转导,免疫疗法和分子病理学研究。吴的一系列成果推动了我国肝脏基础理论研究的创新发展,将其确立为肝胆外科领域的长期国际领导者。这本传记阐明了吴对中国肝胆外科的建立和发展的杰出贡献。
    Wu Mengchao had been engaged in basic and clinical research in hepatobiliary surgery since the 1950s and is recognised as the founder and pioneer of hepatobiliary surgery in China. In his career of over 60 years, Wu performed over 16,000 operations and made numerous breakthroughs in hepatobiliary surgery, liver cancer signal transduction, immunotherapy and molecular pathology research. Wu\'s series of achievements have driven the innovative development of basic theoretical research on the liver in China, establishing it as a long-term international leader in the field of hepatobiliary surgery. This biography elucidates Wu\'s outstanding contributions to the establishment and development of Chinese hepatobiliary surgery.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    阿斯图里亚斯的奇异BRCA1/2突变景观在第一项研究后10年更新。我们分析了1653个指标病例中的BRCA1和BRCA2致病变异。总的来说,238个家族被确定携带致病变异,BRCA1的163个家庭和BRCA2的75个家庭。这产生了14.4%的患病率。发现了七个复发性变异,占病例的55%。其中,三个分布广泛(BRCA1c.21A>G,c.470_471del和c.3331_3334del)和四个在阿斯图里亚斯被报道为新颖:两个在BRCA1中(c.1674del和c.2901_2902dup)和两个在BRCA2中(c.2095C>T和c.4040_4035delinsC)。为所有复发性变体建立了共同的单倍型,表明共有的祖先起源。显示了三个剪接分析:BRCA1:c.51523A>C和BRCA1:c.5333-3T>G,分别导致外显子18和22的跳过,和BRCA1:c.5278-1G>T产生两个转录本,一个缺少外显子21(第Ille1760Glyfs*60)和一个缺少外显子21的前8个核苷酸(p。Phe1761Asnfs*14),支持这些变体的致病性。
    The singular BRCA1/2 mutational landscape of Asturias is updated 10 years after the first study. We analyzed BRCA1 and BRCA2 pathogenic variants in 1653 index cases. In total, 238 families were identified to carry a pathogenic variant, 163 families in BRCA1 and 75 families in BRCA2. This yielded a prevalence rate of 14.4%. Seven recurrent variants were found accounting for 55% of the cases. Among them, three are widely distributed (BRCA1 c.211A>G, c.470_471del and c.3331_3334del) and four had been reported as novel in Asturias: two in BRCA1 (c.1674del and c.2901_2902dup) and two in BRCA2 (c.2095C>T and c.4040_4035delinsC). A common haplotype was established for all recurrent variants indicating a shared ancestral origin. Three splicing analyses are shown: BRCA1:c.5152+3A>C and BRCA1:c.5333-3T>G that lead to skipping of exon 18, and 22 respectively, and BRCA1:c.5278-1G>T giving rise to two transcripts, one lacking exon 21 (p.Ille1760Glyfs*60) and one lacking the first 8 nucleotides of exon 21 (p.Phe1761Asnfs*14), supporting pathogenicity for these variants.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    DSP-心肌病最近被认为是一种特定类型的心肌病。使用内部的孟德尔疾病登记处,我们旨在鉴定具有可能致病性或致病性DSP变异的先证者.我们在4.8%和77.8%的基因型阳性先证中检测到这些变异,这些先证为扩张型和非扩张型左心室心肌病(NDLVC),分别。我们用DSP确定了六个斯洛文尼亚先证者:c.3793G>T,并在分子和表型水平上对它们以及另外八个亲戚进行了表征。医疗记录显示NDLVC有6名患者心律失常(5名先证者,一个亲戚;33±14岁;三名男性,三个女性)。在心脏MRI(CMRI)上,所有人都有心外膜下钆晚期增强,5人收到了ICD.四个人(一个先证者,3名亲属;48±14岁;所有女性)在CMRI上未检测到ECG和/或心脏异常。我们的分析提出了DSP心肌病的斯洛文尼亚特异性分子病理学,描绘了DSP的临床表现:c.3793C>T,从而提高了对与截断DSP变异相关的临床结果的理解。
    DSP-cardiomyopathy has recently been recognised as a specific type of cardiomyopathy. Using an in-house Mendelian disease registry, we aimed to identify probands with likely pathogenic or pathogenic DSP variants. We detected these variants in 4.8% and 77.8% of genotype-positive probands referred for dilated and non-dilated left ventricular cardiomyopathy (NDLVC), respectively. We identified six Slovenian probands with the DSP:c.3793G>T and characterised them along with further eight of their relatives at the molecular and phenotypic level. Medical records revealed NDLVC with arrhythmia in six individuals (five probands, one relative; 33 ± 14 years; three males, three females). All had subepicardial late gadolinium enhancement on cardiac MRI (CMRI), and five received an ICD. Four individuals (one proband, three relatives; 48 ± 14 years; all female) had no ECG and/or cardiac abnormalities on CMRI detected. Our analysis presents a Slovenian-specific molecular pathology of DSP cardiomyopathy, delineates the clinical manifestation of DSP:c.3793C>T, and thereby improves the understanding of the clinical outcomes associated with truncating DSP variants.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    肺发育不全,膈肌异常,无眼症/小眼症,心脏缺陷(PDAC)综合征是一种遗传异质性的多发性先天性畸形综合征。尽管RARB和STRA6中的致病变异是PDAC的确定原因,许多PDAC病例在分子水平上仍未解决。最近,我们基于几个具有PDAC综合征典型特征的家族,提出了双等位基因WNT7B变异体是一种新的病因,尽管其表达能力不同.这里,我们报告了来自两个家庭的三名患者,他们在WNT7B中共享一个新的创始人变体(c.739C>T;Arg247Trp)。该变体的表型表达范围从典型的PDAC特征到分离的泌尿生殖系统异常。与先前报道的PDAC相关WNT7B变体类似,发现该变异体显著损害WNT7B信号活性,进一步证实了其拟议的致病性.该报告为WNT7B相关的PDAC增加了进一步的证据,并扩展了其可变的表达能力。
    Pulmonary hypoplasia, Diaphragmatic anomalies, Anophthalmia/microphthalmia, and Cardiac defects (PDAC) syndrome is a genetically heterogeneous multiple congenital malformation syndrome. Although pathogenic variants in RARB and STRA6 are established causes of PDAC, many PDAC cases remain unsolved at the molecular level. Recently, we proposed biallelic WNT7B variants as a novel etiology based on several families with typical features of PDAC syndrome albeit with variable expressivity. Here, we report three patients from two families that share a novel founder variant in WNT7B (c.739C > T; Arg247Trp). The phenotypic expression of this variant ranges from typical PDAC features to isolated genitourinary anomalies. Similar to previously reported PDAC-associated WNT7B variants, this variant was found to significantly impair WNT7B signaling activity further corroborating its proposed pathogenicity. This report adds further evidence to WNT7B-related PDAC and expands its variable expressivity.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    掌plant角化病(PPK)是一组罕见的皮肤疾病,其特征是手掌或脚底角化过度。亚型分离的点状PPK是由AAGAB中的杂合变体引起的。我们调查了变体AAGABc.370C>T,丹麦南部地区点状PPK患者的p.Arg124Ter代表了创始人的变体,并估计了最新共同祖先的年龄。我们对20例诊断为点状PPK和AAGABc.370C>T的患者的样本进行了单倍型分析,p.Arg124Ter变体。使用Gamma方法,我们计算了最近共同祖先的年份。我们还通过文献和数据库(HGMD,ClinVar,和gnomAD)。我们的分析揭示了3.0Mb的共享单倍型,暗示共同的祖先。祖先单倍群的年龄估计为12.1代(CI:4.9-20.3),相当于约339年(CI:137-568)。这项研究证实,经常观察到的变体AAGABc.370C>T,丹麦南部地区患者的点状PPK中的p.Arg124Ter是由创始人变体引起的。我们建议在我们地区对该变体进行初步筛查,并可能对所有出现点状PPK的丹麦患者进行测试。
    Palmoplantar keratoderma (PPK) is a heterogeneous group of rare skin diseases characterized by hyperkeratosis on the palms or soles. The subtype isolated punctate PPK is caused by heterozygous variants in AAGAB. We investigated if the variant AAGAB c.370C>T, p.Arg124Ter in patients with punctate PPK in the Region of Southern Denmark represented a founder variant and estimated the age to the most recent common ancestor. We performed haplotype analysis on samples from 20 patients diagnosed with punctate PPK and the AAGAB c.370C>T, p.Arg124Ter variant. Using the Gamma Method, we calculated the years to the most recent common ancestor. We also explored the presence of the variant in other populations through literature and databases (HGMD, ClinVar, and gnomAD). Our analysis revealed a shared haplotype of 3.0 Mb, suggesting shared ancestry. The ancestral haplogroup was estimated to an age of 12.1 generations (CI: 4.9-20.3) equivalent to approximately 339 years (CI: 137-568). This study confirms that the frequently observed variant AAGAB c.370C>T, p.Arg124Ter in punctate PPK among patients in the Region of Southern Denmark is caused by a founder variant. We recommend testing for the variant as initial screening in our region and potentially for all Danish patients presenting with punctate PPK.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    创始人致病变异(PV)在以色列很普遍。这项研究调查了目前为癌症患者提供两步基因检测的做法,从针对经常性创始人PV的针对性测试开始,跟着,如果是否定的,通过下一代测序。2020年3月至2023年1月,共有2128名患有癌症或家族史阳性的受试者在三级医疗中心接受了51个复发性PV小组的致癌基因检测。具有已知家族性PV(n=370)的那些被排除在分析之外。其余的,128/1758(7%)至少有一个变体是杂合的,44例(34%)携带中高外显率(MHPV)的PV。在1519/1758患者中诊断出癌症(86%)。创始人MHPV检测的诊断率在癌症患者中为2%,在具有阳性家族史的健康个体中为4%。阿什肯纳齐犹太人比非阿什肯纳齐犹太人和阿拉伯人高,但任何类型的癌症都不超过10%,年轻人(<40岁)明显高于老年人(>50岁)(7%vs.1%)。84个杂合子(66%),主要是阿什肯纳齐犹太人,带有与诊断出的癌症无关的低外显率变体(LPV),通常是APCc.3902T>A.这些发现质疑两步测试的优势。LPV不应被包括在有针对性的测试中,因为这会导致过高估计产量,它们的检测并不排除进一步的全面检测。
    Founder pathogenic variants (PVs) are prevalent in Israel. This study investigated the current practice of offering cancer patients two-step genetic testing, starting with targeted testing for recurring founder PVs, followed, if negative, by next-generation sequencing. A total of 2128 subjects with cancer or a positive family history underwent oncogenetic testing with a panel of 51 recurring PVs at a tertiary medical center in March 2020-January 2023. Those with a known familial PV (n = 370) were excluded from the analysis. Among the remainder, 128/1758 (7%) were heterozygous for at least one variant, and 44 (34%) carried a PV of medium-high penetrance (MHPV). Cancer was diagnosed in 1519/1758 patients (86%). The diagnostic yield of founder MHPV testing was 2% in cancer patients and 4% in healthy individuals with a positive family history. It was higher in Ashkenazi Jews than non-Ashkenazi Jews and Arabs, but not over 10% for any type of cancer, and it was significantly higher in younger (<40 years) than older (>50 years) individuals (7% vs. 1%). Eighty-four of the heterozygotes (66%), mostly Ashkenazi Jews, harbored a low-penetrance variant (LPV) not associated with the diagnosed cancer, usually APC c.3902T>A. These findings question the advantage of two-step testing. LPVs should not be included in targeted testing because this can lead to an overestimation of the yield, and their detection does not preclude further comprehensive testing.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:TGFB3变异导致Loeys-Dietz综合征5型,一种胸主动脉瘤和夹层的综合征形式。确切的疾病表型很难描述,因为很少有确定的病例和高度可变的临床表现。方法:我们提供了来自5个不同家庭的27个个体的临床特征的单倍型分析和病历回顾的结果。起源于法兰德斯的坎平地区,携带NM_003239.5(TGFB3):c.787G>Cp。(Asp263His)可能致病变异,dbSNP:rs796051886,ClinVar:203492。Asp263残基对于整联蛋白结合TGFβ3-细胞因子的Arg-Gly-Asp(RGD)基序是必需的。结果:单倍型分析揭示了最小1.92Mb和最大4.14Mb的共享单倍型,暗示一个共同的创始人起源于400多年前。可变的临床特征包括结缔组织表现,非动脉瘤性心血管问题,如肥厚型心肌病,二叶主动脉瓣,二尖瓣疾病,和间隔缺损。值得注意的是,只有在27个变异个体中的4个,观察到明显的主动脉受累.在一个家庭里,一名31岁男性出现A型解剖。在另一个家庭,男性先证者(65岁)因主动脉瓣二尖瓣关闭不全合并50mmValsalva窦而接受了Bentall手术,而一名80岁的男性亲属的主动脉直径为43毫米。在第三个家庭中,先证者的父亲(75岁)出现升主动脉瘤(44毫米)。结论:主动脉瘤/夹层的低外显率(15%)表明TGFB3变体单独的单倍体功能不全可能不会导致动脉瘤的发展,但需要其他因素来引起动脉瘤表型。
    Background: TGFB3 variants cause Loeys-Dietz syndrome type 5, a syndromic form of thoracic aortic aneurysm and dissection. The exact disease phenotype is hard to delineate because of few identified cases and highly variable clinical representation. Methodology: We provide the results of a haplotype analysis and a medical record review of clinical features of 27 individuals from 5 different families, originating from the Campine region in Flanders, carrying the NM_003239.5(TGFB3):c.787G>C p.(Asp263His) likely pathogenic variant, dbSNP:rs796051886, ClinVar:203492. The Asp263 residue is essential for integrin binding to the Arg-Gly-Asp (RGD) motif of the TGFβ3-cytokine. Results: The haplotype analysis revealed a shared haplotype of minimum 1.92 Mb and maximum 4.14 Mb, suggesting a common founder originating >400 years ago. Variable clinical features included connective tissue manifestations, non-aneurysmal cardiovascular problems such as hypertrophic cardiomyopathy, bicuspid aortic valve, mitral valve disease, and septal defects. Remarkably, only in 4 out of the 27 variant-harboring individuals, significant aortic involvement was observed. In one family, a 31-year-old male presented with type A dissection. In another family, the male proband (65 years) underwent a Bentall procedure because of bicuspid aortic valve insufficiency combined with sinus of Valsalva of 50 mm, while an 80-year-old male relative had an aortic diameter of 43 mm. In a third family, the father of the proband (75 years) presented with ascending aortic aneurysm (44 mm). Conclusion: The low penetrance (15%) of aortic aneurysm/dissection suggests that haploinsufficiency alone by the TGFB3 variant may not result in aneurysm development but that additional factors are required to provoke the aneurysm phenotype.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Editorial
    随着数字健康领域的发展和发展,在卫生保健方面迫切需要证据和基于理论的干预措施.将科学融入商业的必要性比以往任何时候都更加关键。为了开发可持续和可扩展的产品,公司需要了解这个行业的科学家,可以制定符合业务重点的科学战略,并且能够跨功能应用科学。在这篇文章中,我分享了我对行业科学家的角色和责任所获得的见解,以及我在成为独角兽的数字健康初创公司担任科学主管5年后学到的经验教训。
    As the field of digital health grows and evolves, there is a critical need for evidence and theory-based interventions in health care. The need for integration of science into business is more critical than ever. To develop sustainable and scalable products, companies need scientists who understand the industry, can develop scientific strategy that aligns with business priorities, and are able to apply science cross-functionally. In this article, I share the insights I have gained about the roles and responsibilities of industry scientists and the lessons I have learned after spending 5 years as the head of science for a digital health start-up that turned unicorn.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    分子尸检是指基于DNA的死因鉴定。尽管最近试图扩大其范围,该术语通常保留给年轻人不明原因的猝死。在这项研究中,我们的目的是展示分子尸检在定义人类致命变异中的实用性。
    我们描述了我们对481例病例的经验,其中使用来自索引或亲属的DNA(通过代理进行分子尸检)调查了过早死亡的原因。分子尸检工具通常是外显子组测序,尽管在研究的早期阶段使用靶向方法进行了研究;这些包括位置映射,靶向基因测序,染色体微阵列,和基因面板。
    该研究包括来自近亲家庭的449例病例和141例缺乏家族史(单纯性)。胚胎的年龄范围是18岁。在63.8%(307/481)中发现了可能的因果变异(致病性/可能致病性),与同一人群的一般诊断产量(43%)相比,产量要高得多。隐性致死等位基因的优势使我们能够通过代理对55对夫妇进行分子尸检,产率同样高(63.6%)。我们还注意到典型的非致死性显性疾病的双等位基因致死形式的发生,有时代表一种新的真正的双等位基因隐性疾病特征。在本研究过程中鉴定了46个无OMIM表型的疾病基因。提供的数据支持另外两个先前报道的新疾病基因(FAAH2和MSN)的候选资格。对致死表型的关注揭示了许多有趣的表型扩展以及临床表现中的显着变异性的例子。此外,根据结果,强调了对群体遗传学和变异解释的重要见解。
    分子尸检,广义定义,被证明是一种有用的临床方法,可提供对致命变异和人类基因组临床注释的独特见解。
    Molecular autopsy refers to DNA-based identification of the cause of death. Despite recent attempts to broaden its scope, the term remains typically reserved to sudden unexplained death in young adults. In this study, we aim to showcase the utility of molecular autopsy in defining lethal variants in humans.
    We describe our experience with a cohort of 481 cases in whom the cause of premature death was investigated using DNA from the index or relatives (molecular autopsy by proxy). Molecular autopsy tool was typically exome sequencing although some were investigated using targeted approaches in the earlier stages of the study; these include positional mapping, targeted gene sequencing, chromosomal microarray, and gene panels.
    The study includes 449 cases from consanguineous families and 141 lacked family history (simplex). The age range was embryos to 18 years. A likely causal variant (pathogenic/likely pathogenic) was identified in 63.8% (307/481), a much higher yield compared to the general diagnostic yield (43%) from the same population. The predominance of recessive lethal alleles allowed us to implement molecular autopsy by proxy in 55 couples, and the yield was similarly high (63.6%). We also note the occurrence of biallelic lethal forms of typically non-lethal dominant disorders, sometimes representing a novel bona fide biallelic recessive disease trait. Forty-six disease genes with no OMIM phenotype were identified in the course of this study. The presented data support the candidacy of two other previously reported novel disease genes (FAAH2 and MSN). The focus on lethal phenotypes revealed many examples of interesting phenotypic expansion as well as remarkable variability in clinical presentation. Furthermore, important insights into population genetics and variant interpretation are highlighted based on the results.
    Molecular autopsy, broadly defined, proved to be a helpful clinical approach that provides unique insights into lethal variants and the clinical annotation of the human genome.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    Personal factors such as the founder\'s values and psychological characteristics will influence founder\'s vision, his perception and interpretation of the decision-making environment, and his strategic choice and decision-making. Based on the theory of entrepreneurial characteristics, combined with the founder\'s unique psychological characteristics, this paper takes Chinese private listed companies between 2010 and 2018 as a research sample to study the effect of the founder of private enterprises on corporate social responsibility. Furthermore, this study analyzes the impact of different management roles of the founder on corporate social responsibility. We demonstrate that the private enterprises have better social responsibility performance when there are founders; the founders have different management roles, and their corporate social responsibility performance has certain differences, and the higher the management level of the founders, the better the corporate social responsibility performance. This paper studies the issue of corporate social responsibility from the perspective of the characteristics of founders, which expands the current framework of corporate social responsibility research and provides an empirical basis for founders to effectively participate in corporate management in practice.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号